Erythropoeitin and darbepoetin, both ESAs, are often used to treat anaemia in cancer, but there have been some concerns that they increase the risk of venous thromboembolism (VTE).
The latest research involved a review of 51 phase 3 trials that compared ESAs with placebo for treating anaemia in cancer.
Together, they included 13,611 patients. This showed that the risk of death was significantly higher in cancer patients given ESAs than those on placebo.
Further analysis of 38 trials, including 8,172 patients, showed there was a 57 per cent increased risk of VTE in patients treated with an ESA than those in the control groups.
The findings raise concerns about giving ESAs to cancer patients, say the researchers.
JAMA 2008; 299: 914-24
Comment below and tell us what you think